Shelby Derene Reed, PhD has been promoted to Full Professor of Medicine by the Duke University School of Medicine Board of Trustees, effective May 1, 2014! Shelby’s appointment to this highest academic rank reflects the tremendous impact of her work to improve human health, her continuous exemplary scholarship, and the extraordinarily high esteem she has garnered as a preeminent scholar among her peers nationally and internationally.
Shelby has spent her distinguished career studying economic and health outcomes of pharmaceuticals and health care services across a range of therapeutic areas including infectious diseases, oncology, dermatology, cardiovascular disease, and cerebrovascular disease. She has also studied the potential economic impact of trends in clinical trial design, changes in reimbursement policies, and the development of larger pre-market databases to identify drug safety issues. Her leadership in these areas has been reflected by her election to serve on numerous national and international committees, including the Board of Directors of the International Society of Pharmacoeconomics and Outcomes Research. Shelby has been the principal investigator on NIH funded studies, and her work has been featured in the most prestigious international journals. Shelby is widely regarded as a superb collaborator and mentor.
Congratulations, Shelby, on this truly fitting recognition of your outstanding achievements!
Shelby Derene Reed, PhD has been promoted to Full Professor of Medicine by the Duke University School of Medicine Board of Trustees, effective May 1, 2014! Shelby’s appointment to this highest academic rank reflects the tremendous impact of her work to improve human health, her continuous exemplary scholarship, and the extraordinarily high esteem she has garnered as a preeminent scholar among her peers nationally and internationally.
Shelby has spent her distinguished career studying economic and health outcomes of pharmaceuticals and health care services across a range of therapeutic areas including infectious diseases, oncology, dermatology, cardiovascular disease, and cerebrovascular disease. She has also studied the potential economic impact of trends in clinical trial design, changes in reimbursement policies, and the development of larger pre-market databases to identify drug safety issues. Her leadership in these areas has been reflected by her election to serve on numerous national and international committees, including the Board of Directors of the International Society of Pharmacoeconomics and Outcomes Research. Shelby has been the principal investigator on NIH funded studies, and her work has been featured in the most prestigious international journals. Shelby is widely regarded as a superb collaborator and mentor.
Congratulations, Shelby, on this truly fitting recognition of your outstanding achievements!